A recycling anti-transferrin receptor-1 monoclonal antibody as an efficient therapy for erythroleukemia through target up-regulation and antibody-dependent cytotoxic effector functions

Neiveyans, Madeline; Melhem, Rana; Arnoult, Christophe; Bourquard, Thomas; Jarlier, Marta; Busson, Muriel; Laroche, Adrien; Cérutti, Martine; Pugnière, Martine; Ternant, David; Gaborit, Nadège; Chardès, Thierry; Poupon, Anne; Gouilleux-Gruart, Valérie; Pèlegrin, André; Poul, Marie‐Alix

doi:10.1080/19420862.2018.1564510

Cited by 18 publications

(21 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The third fully human antibody that has been developed is the H7 neutralizing IgG1 antibody (H7-IgG1) for which the variable regions from the 3GH7 scFv described above were used to produce a human IgG1 antibody ( 175 ). Another version of this antibody was produced containing two scFvs linked to the Fc region of human IgG1 (H7-Fc).…”

Section: Targeting Tfr1 For Cancer Therapymentioning

confidence: 99%

“…Interestingly, only the H7-Fc was able to bind human and mouse TfR1, while the full length H7-IgG1 antibody was only able to bind human TfR1. Both forms of the H7 antibody inhibited the in vitro growth and induced apoptosis in human ERY-1 erythroleukemia cells, and human Raji BL cells ( 175 ). Both formats also induced ADCC activity, but the H7-IgG1 showed more potent ADCC activity ( 175 ).…”

Section: Targeting Tfr1 For Cancer Therapymentioning

confidence: 99%

“…Both forms of the H7 antibody inhibited the in vitro growth and induced apoptosis in human ERY-1 erythroleukemia cells, and human Raji BL cells ( 175 ). Both formats also induced ADCC activity, but the H7-IgG1 showed more potent ADCC activity ( 175 ). Tumor regression was observed in nude mice treated with 100 μg H7-Fc (i.p injection twice a week for 4 weeks) bearing ERY-1 erythroleukemia cells xenografts, but significant prolongation of survival was not observed ( 175 ).…”

Section: Targeting Tfr1 For Cancer Therapymentioning

confidence: 99%

See 2 more Smart Citations

Antibodies Targeting the Transferrin Receptor 1 (TfR1) as Direct Anti-cancer Agents

et al. 2021

View full text Add to dashboard Cite

The transferrin receptor 1 (TfR1), also known as cluster of differentiation 71 (CD71), is a type II transmembrane glycoprotein that binds transferrin (Tf) and performs a critical role in cellular iron uptake through the interaction with iron-bound Tf. Iron is required for multiple cellular processes and is essential for DNA synthesis and, thus, cellular proliferation. Due to its central role in cancer cell pathology, malignant cells often overexpress TfR1 and this increased expression can be associated with poor prognosis in different types of cancer. The elevated levels of TfR1 expression on malignant cells, together with its extracellular accessibility, ability to internalize, and central role in cancer cell pathology make this receptor an attractive target for antibody-mediated therapy. The TfR1 can be targeted by antibodies for cancer therapy in two distinct ways: (1) indirectly through the use of antibodies conjugated to anti-cancer agents that are internalized by receptor-mediated endocytosis or (2) directly through the use of antibodies that disrupt the function of the receptor and/or induce Fc effector functions, such as antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cell-mediated phagocytosis (ADCP), or complement-dependent cytotoxicity (CDC). Although TfR1 has been used extensively as a target for antibody-mediated cancer therapy over the years, interest continues to increase for both targeting the receptor for delivery purposes and for its use as direct anti-cancer agents. This review focuses on the developments in the use of antibodies targeting TfR1 as direct anti-tumor agents.

show abstract

Section: Targeting Tfr1 For Cancer Therapymentioning

confidence: 99%

Section: Targeting Tfr1 For Cancer Therapymentioning

confidence: 99%

Section: Targeting Tfr1 For Cancer Therapymentioning

confidence: 99%

See 1 more Smart Citation

Antibodies Targeting the Transferrin Receptor 1 (TfR1) as Direct Anti-cancer Agents

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Recent studies have reported that TFR1 is involved in kinds of diseases, including cancers, anaemia, and neurodegenerative diseases. Most importantly, TFR1 was verified to be abnormally expressed in various cancers, and some experimental and clinical drugs and antibodies targeting this protein have shown strong anti-tumour effects [38][39][40][41][42][43][44][45][46]; herein, TFR1 is suggested to be a potential molecular biomarker for targeted cancer diagnosis and therapy. SAHH, encoded by the AHCY gene, belongs to the adenosylhomocysteinase family and is a competitive inhibitor of S-adenosyl-L-methionine-dependent methyltransferase reactions and might play a key role in the control of methylation by regulating the intracellular concentration of adenosylhomocysteine.…”

Section: Discussionmentioning

confidence: 99%

Proteomics study of colorectal cancer and adenomatous polyps identifies TFR1, SAHH, and HV307 as potential biomarkers for screening

Tang

Zeng²,

Zeng

et al. 2020

Preprint

View full text Add to dashboard Cite

Colorectal cancer (CRC) is a malignant tumour with high morbidity and mortality worldwide. Efficient screening strategies for CRC and pre-cancerous lesions will promote early medical intervention and treatment, thus reducing morbidity and mortality. Proteins are generally considered key biomarkers of cancer. Herein, we performed a quantitative, tissue-original proteomics study in a cohort of ninety patients from pre-cancerous to cancerous conditions by liquid chromatography-tandem mass spectrometry. A total of 134,812 peptides, 8,697 proteins, 2,355 (27.08%) union differentially expressed proteins (DEPs), and 409 shared DEPs (compared with adjacent tissues) were identified. The number of DEPs showed a positive correlation with increasing severity of illness. The union and shared DEPs were both enriched in the KEGG pathway of focal adhesion, metabolism of xenobiotics by cytochrome P450, and drug metabolism - cytochrome P450. Among the 2,355 union DEPs, 32 were selected for identification and validation by multiple reaction monitoring from twenty plasma specimens. Of these, three proteins, transferrin receptor protein 1 (TFR1), adenosylhomocysteinase (SAHH), and immunoglobulin heavy variable 3-7 (HV307), were significantly differentially expressed and displayed the same expression pattern in plasma as observed in the tissue data. In conclusion, TFR1, SAHH, and HV307 may be considered as potential biomarkers for screening of CRC.

show abstract

“…In single chain variable fragment (scFV) small peptide linker connects the VH and VL chain. When an antibody against anti-transferrin receptor-1 (TfR1) was re-engineered from anti-human TfR1 single-chain variable fragment (scFv) antibodies into fully human scFV2-Fcγ1 and IgG1 antibodies; it resulted in a better candidate of antibody therapy for leukemia and lymphoma [48].…”

Section: Monoclonal Antibody For Leukemia Treatmentmentioning

confidence: 99%

Development of Therapeutic Antibody Technology And Recent Perspectives For Leukemia-Lymphoma Treatment

Yirga¹,

Lin²,

Huang³

et al. 2019

J Leuk

View full text Add to dashboard Cite

Advancement of monoclonal antibodies (Mabs) to be accepted as a therapy has long history. This article describes the dramatic developmental trend of therapeutic antibody technology and their significant role for treatment of leukemia-lymphoma at the current time. The therapeutic Mab technology development from murine (mouse origin) to fully human resulted in low immunogenicity and high quality Mabs. Chemotherapy is standard care for leukemialymphoma treatments. However, it is associated with high toxicities (side effects), painful and relatively ineffective against certain leukemia-lymphoma subtypes. The remarkable contribution of Von Behring, Paul Ehrlich and the discovery of hybridoma technology marked the beginning of antibodies for therapeutic applications. Rituximab is the first Mab approved by Food and Drug Administration against B-cell malignancies. Today, a number of effective Mabs targeting leukemia and lymphoma were approved and successfully developed. The Mab therapeutic phenomena in the body (also called war in the blood) has various mechanism of actions. In recent years, Mab against leukemialymphoma achieved significantly therapeutic outcomes, eventually this led to traditional chemotherapy treatment free era. We also reviewed that, the therapeutic efficacy of Mabs against leukemia-lymphoma as compared antibody alone and antibody conjugated with potent chemotherapy or cytotoxic drugs. This article extends our understanding of advancements in therapeutic Mabs technology and provides new insights of Mab leukemia-lymphomas therapy. We also encourage further more studies for Mab based diagnostics, treatments of leukemia and lymphomas.

show abstract

A recycling anti-transferrin receptor-1 monoclonal antibody as an efficient therapy for erythroleukemia through target up-regulation and antibody-dependent cytotoxic effector functions

Cited by 18 publications

References 47 publications

Antibodies Targeting the Transferrin Receptor 1 (TfR1) as Direct Anti-cancer Agents

Antibodies Targeting the Transferrin Receptor 1 (TfR1) as Direct Anti-cancer Agents

Proteomics study of colorectal cancer and adenomatous polyps identifies TFR1, SAHH, and HV307 as potential biomarkers for screening

Development of Therapeutic Antibody Technology And Recent Perspectives For Leukemia-Lymphoma Treatment

Contact Info

Product

Resources

About